Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10525053 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(8 months ago) | |
US9248195 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(8 months ago) | |
US8840928 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(8 months ago) | |
US10525052 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(8 months ago) | |
US9044398 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Jul, 2023
(8 months ago) | |
US9592200 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(8 months ago) | |
US9763883 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(8 months ago) | |
US8557291 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Mar, 2025
(11 months from now) | |
US8449909 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(11 months from now) | |
US7399488 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar, 2025
(11 months from now) | |
US7771707 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(11 months from now) | |
US8758813 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jun, 2025
(1 year, 2 months from now) | |
US10004729 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
US10668060 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
US9682075 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
US9737530 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
US10188644 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
US9968598 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
US10646485 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) |
Xtampza Er is owned by Collegium Pharm Inc.
Xtampza Er contains Oxycodone.
Xtampza Er has a total of 19 drug patents out of which 7 drug patents have expired.
Expired drug patents of Xtampza Er are:
Xtampza Er was authorised for market use on 26 April, 2016.
Xtampza Er is available in capsule, extended release;oral dosage forms.
Xtampza Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The generics of Xtampza Er are possible to be released after 02 September, 2036.
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE;ORAL